ADCs in Bladder Cancer With Petros Grivas, MD, PhD

By The Uromigos - Last Updated: August 1, 2023

Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug’s EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial.
Dr. Grivas is a professor in the Division of Medical Oncology at the University of Washington School of Medicine, as well as a physician at Fred Hutch Cancer Center.

Post Tags:Uromigos-Bladder Cancer